Table 3.
Systemic and pulmonary hemodynamic parameters in controls, with acetazolamide iv, acetazolamide po, inhaled acetazolamide, methazolamide iv, and N-methyl-acetazolamide iv during normoxia and hypoxia
| n | Normoxia 1 h | Hypoxia 1st h | Hypoxia 2nd h | |
|---|---|---|---|---|
| HR, 1/min | ||||
| Series 1 | ||||
| Controls | 7 | 78 ± 12 | 108 ± 24* | 101 ± 20 |
| ACZ iv | 7 | 71 ± 11 | 98 ± 16 | 95 ± 20 |
| ACZ po | 7 | 86 ± 6 | 109 ± 16 | 100 ± 16 |
| ACZ inhaled | 7 | 85 ± 16 | 85 ± 20 | 97 ± 23 |
| Series 2 | ||||
| Controls | 9 | 75 ± 8 | 111 ± 17* | 110 ± 14* |
| ACZ iv | 8 | 75 ± 10 | 100 ± 20* | 102 ± 18* |
| MTZ iv | 6 | 74 ± 15 | 96 ± 6 | 93 ± 12 |
| NMA iv | 6 | 72 ± 11 | 112 ± 17* | 110 ± 15* |
| MAP, mmHg | ||||
| Series 1 | ||||
| Controls | 7 | 95 ± 8 | 106 ± 11 | 105 ± 25 |
| ACZ iv | 7 | 89 ± 10 | 104 ± 15 | 108 ± 15 |
| ACZ po | 7 | 96 ± 4 | 109 ± 13 | 108 ± 17 |
| ACZ inhaled | 7 | 93 ± 10 | 105 ± 16 | 106 ± 15 |
| Series 2 | ||||
| Controls | 9 | 94 ± 11 | 103 ± 11 | 100 ± 18 |
| ACZ iv | 8 | 88 ± 8 | 101 ± 7 | 103 ± 12 |
| MTZ iv | 6 | 90 ± 10 | 105 ± 20 | 103 ± 18 |
| NMA iv | 6 | 89 ± 10 | 109 ± 10 | 103 ± 16 |
| CO, l/min | ||||
| Series 1 | ||||
| Controls | 7 | 2.7 ± 0.5 | 2.9 ± 0.6 | 2.7 ± 0.4 |
| ACZ iv | 7 | 2.3 ± 0.5 | 2.5 ± 0.4 | 2.3 ± 0.3 |
| ACZ po | 7 | 2.5 ± 0.6 | 2.8 ± 0.6 | 2.4 ± 0.4 |
| ACZ inhaled | 7 | 2.6 ± 0.4 | 2.4 ± 0.4 | 2.5 ± 0.3 |
| Series 2 | ||||
| Controls | 9 | 2.3 ± 0.6 | 2.8 ± 0.6 | 2.7 ± 0.5 |
| ACZ iv | 8 | 2.2 ± 0.9 | 2.5 ± 0.6 | 2.5 ± 0.6 |
| MTZ iv | 6 | 2.2 ± 0.6 | 2.8 ± 0.8 | 2.6 ± 0.9 |
| NMA iv | 6 | 2.7 ± 0.7 | 3.3 ± 1.0 | 3.3 ± 0.9 |
| SVR, dyn·s·cm−5 | ||||
| Series 1 | ||||
| Controls | 7 | 2,896 ± 659 | 2,907 ± 680 | 3,135 ± 793 |
| ACZ iv | 7 | 3,101 ± 838 | 3,354 ± 708 | 3,759 ± 844 |
| ACZ po | 7 | 3,227 ± 849 | 3,147 ± 818 | 3,633 ± 848 |
| ACZ inhaled | 7 | 2,880 ± 515 | 3,519 ± 618 | 3,400 ± 572 |
| Series 2 | ||||
| Controls | 9 | 3,351 ± 874 | 2,940 ± 648 | 3,004 ± 587 |
| ACZ iv | 8 | 3,470 ± 1,049 | 3,223 ± 660 | 3,369 ± 1,021 |
| MTZ iv | 6 | 2,541 ± 614 | 2,294 ± 401 | 2,538 ± 309 |
| NMA iv | 6 | 2,735 ± 899 | 2,751 ± 779 | 2,532 ± 501 |
| CVP, mmHg | ||||
| Series 1 | ||||
| Controls | 7 | 2 ± 1 | 2 ± 1 | 2 ± 1 |
| ACZ iv | 7 | 2 ± 1 | 2 ± 1 | 2 ± 1 |
| ACZ po | 7 | 2 ± 1 | 2 ± 1 | 2 ± 1 |
| ACZ inhaled | 7 | 3 ± 1 | 2 ± 1 | 2 ± 1 |
| Series 2 | ||||
| Controls | 9 | 2 ± 1 | 2 ± 1 | 2 ± 1 |
| ACZ iv | 8 | 3 ± 1 | 2 ± 1 | 3 ± 0 |
| MTZ iv | 6 | 2 ± 1 | 3 ± 1 | 2 ± 1 |
| NMA iv | 6 | 3 ± 1 | 2 ± 0 | 3 ± 1 |
| MPAP, mmHg | ||||
| Series 1 | ||||
| Controls | 7 | 13 ± 2 | 20 ± 2* | 20 ± 3* |
| ACZ iv | 7 | 12 ± 2 | 14 ± 2† | 13 ± 2† |
| ACZ po | 7 | 13 ± 2 | 17 ± 2* | 17 ± 3* |
| ACZ inhaled | 7 | 13 ± 2 | 15 ± 2† | 15 ± 3† |
| Series 2 | ||||
| Controls | 9 | 11 ± 2 | 18 ± 2* | 18 ± 2* |
| ACZ iv | 8 | 11 ± 3 | 14 ± 3† | 13 ± 3† |
| MTZ iv | 6 | 11 ± 1 | 15 ± 3* | 14 ± 3 |
| NMA iv | 6 | 13 ± 2 | 17 ± 3 | 16 ± 4 |
| PVR, dyn·s·cm−5 | ||||
| Series 1 | ||||
| Controls | 7 | 265 ± 52 | 463 ± 110* | 489 ± 87* |
| ACZ iv | 7 | 284 ± 81 | 354 ± 80 | 350 ± 74† |
| ACZ po | 7 | 292 ± 35 | 385 ± 107 | 470 ± 145 |
| ACZ inhaled | 7 | 284 ± 47 | 378 ± 88 | 386 ± 91 |
| Series 2 | ||||
| Controls | 9 | 256 ± 70 | 405 ± 88* | 444 ± 85* |
| ACZ iv | 8 | 269 ± 66 | 305 ± 70 | 300 ± 87† |
| MTZ iv | 6 | 244 ± 49 | 329 ± 90 | 325 ± 81 |
| NMA iv | 6 | 262 ± 62 | 321 ± 86 | 330 ± 85 |
| PCWP, mmHg | ||||
| Series 1 | ||||
| Controls | 7 | 4 ± 1 | 3 ± 0 | 4 ± 1 |
| ACZ iv | 7 | 4 ± 1 | 3 ± 1 | 3 ± 1 |
| ACZ po | 7 | 4 ± 1 | 4 ± 1 | 4 ± 1 |
| ACZ inhaled | 7 | 4 ± 1 | 4 ± 1 | 4 ± 0 |
| Series 2 | ||||
| Controls | 9 | 4 ± 0 | 4 ± 1 | 4 ± 1 |
| ACZ iv | 8 | 4 ± 1 | 4 ± 1 | 4 ± 1 |
| MTZ iv | 6 | 5 ± 1 | 4 ± 1 | 4 ± 1 |
| NMA iv | 6 | 4 ± 1 | 4 ± 1 | 4 ± 1 |
Values are mean ± SD; n, no. of experiments.
HR, heart rate; MAP, mean arterial pressure; CO, cardiac output; SVR, systemic vascular resistance; CVP, central venous pressure; MPAP, mean pulmonary artery pressure; PVR, pulmonary vascular resistance; PCWP, pulmonary capillary wedge pressure.
Significant differences (P < 0.05) vs.
*
normoxia and
†
controls at equal time points.